| Literature DB >> 33431812 |
Jue-Sheng Ong1, Suzanne C Dixon-Suen2, Xikun Han3,4, Jiyuan An5, Upekha Liyanage6, Jean-Cluade Dusingize7, Johannes Schumacher8, Ines Gockel9, Anne Böhmer10, Janusz Jankowski11,12, Claire Palles13, Tracy O'Mara14, Amanda Spurdle14, Matthew H Law3, Mark M Iles15, Paul Pharoah16, Andrew Berchuck17, Wei Zheng18, Aaron P Thrift19, Catherine Olsen4,7, Rachel E Neale20, Puya Gharahkhani3, Penelope M Webb21, Stuart MacGregor3.
Abstract
Previous Mendelian randomization (MR) studies on 25-hydroxyvitamin D (25(OH)D) and cancer have typically adopted a handful of variants and found no relationship between 25(OH)D and cancer; however, issues of horizontal pleiotropy cannot be reliably addressed. Using a larger set of variants associated with 25(OH)D (74 SNPs, up from 6 previously), we perform a unified MR analysis to re-evaluate the relationship between 25(OH)D and ten cancers. Our findings are broadly consistent with previous MR studies indicating no relationship, apart from ovarian cancers (OR 0.89; 95% C.I: 0.82 to 0.96 per 1 SD change in 25(OH)D concentration) and basal cell carcinoma (OR 1.16; 95% C.I.: 1.04 to 1.28). However, after adjustment for pigmentation related variables in a multivariable MR framework, the BCC findings were attenuated. Here we report that lower 25(OH)D is unlikely to be a causal risk factor for most cancers, with our study providing more precise confidence intervals than previously possible.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33431812 PMCID： PMC7801600 DOI： 10.1038/s41467-020-20368-w
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919